DMD Celsis microsomes mean better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on November 15, 2006; DOI: 10.1124/dmd.106.012922


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.012922v1
35/2/221    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, J.
Right arrow Articles by Cooper, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, J.
Right arrow Articles by Cooper, G. J.


Received for publication September 22, 2006.
Revised November 7, 2006.
Accepted for publication November 8, 2006.

Triethylenetetramine (TETA) and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type-2 diabetic patients

Jun Lu 1, Yi-Kai Chan 1, Gregory D Gamble 1, Sally D Poppitt 1, Asma A Othman 1, Garth JS Cooper 1*

1 University of Auckland

* Address correspondence to: E-mail: g.cooper{at}auckland.ac.nz

Abstract

Triethylenetetramine (TETA), a selective CuII-chelator used in the treatment of Wilson's disease, is now undergoing clinical trials for the treatment of heart failure in diabetes. Despite decades of clinical use, knowledge of its pharmacology in human subjects remains incomplete. Here, we first used liquid chromatography- mass spectrometry (LC-MS) to detect and identify major metabolites of TETA in human plasma and urine, and then used this method to measure concentrations of TETA and its metabolites in the urine of healthy and diabetic subjects. Healthy and diabetic subjects were administered various doses (300, 600, 1200 and 2400 mg) of TETA orally. Twenty-four-hour urine collections were performed before and after dosing participants. Two major metabolites of TETA were detected in human urine, N1-acetyltriethylenetetramine (MAT) and N1,N10- diacetyltriethylenetetramine, the latter being novel. Both metabolites were verified by synthetic standards on LC-MS. The proportion of unchanged TETA excreted as a fraction of total urinary drug-derived molecules, was significantly higher in healthy than in matched diabetic subjects, consistent with a higher rate of TETA metabolism in the latter. TETA-evoked increases in urinary Cu excretion in non-diabetic subjects were more closely correlated with parent drug concentrations than in diabetic subjects whereas, by contrast, urinary Cu was more closely associated with the sum of TETA and MAT. These findings are consistent with the hypothesis that MAT could play a significant role in the molecular mechanism by which TETA extracts CuII from the systemic compartment in diabetic subjects.


Key words: acetylation, drug analysis, excretion, HPLC, mass spectrometry, metabolite identification, phase II drug metabolism





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.